Omega-3 Memory Meta-analysis: What the Evidence Says

Quick Answer

Omega-3 Memory Meta-analysis has 3 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 research article, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Concurrently, the number of individuals affected by dementia is anticipated to nearly triple by 2050, with associated treatment costs projected to reach US$2.8 trillion by 2030. [Liu Xing (2026); evidence level 1]
• In addition, omega-3 fatty acids support synaptic plasticity and exert anti-inflammatory effects; however, evidence is mixed, as randomized trials in healthy older adults show limited benefits, while several analyses report modest improvements in aged or MCI patients. [Liu Xing (2026); evidence level 1]
• Consequently, identifying modifiable risk factors to prevent or delay cognitive decline is of critical public health importance. [Liao Zheng-Bin (2026); evidence level 4]
• By elucidating these specific neurobiological pathways, we aim to provide clinical evidence that informs the debate regarding the role of omega-3 fatty acids supplementation in slowing cognitive decline. [Liao Zheng-Bin (2026); evidence level 4]
• Following expert review and pilot testing, the scale was reduced to nine-items comprising five meta-memory and four meta-concentration items. [Adesola Adeniyi Abraham (2026); evidence level 4]
• Model B demonstrated improved fit indices (χ² (23) = 52.5,= 0.001; CFI = 0.974; TLI = 0.959; RMSEA = 0.066; SRMR = 0.041; GFI = 0.965; PCLOSE = 0.127), with a lower χ²/df ratio (2.284) compared to Model A (2.952), indicating a better fit to the data. [Adesola Adeniyi Abraham (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For omega-3 memory meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Liu Xing (2026). Nutritional supplements and cognition in healthy aging and mild cognitive impairment patients: a systematic review and network meta-analysis. DOI: 10.1016/j.tjpad.2026.100518. PMCID: PMC12966656. PMID: 41764841. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12966656/
• Liao Zheng-Bin (2026). The association between omega-3 supplementation and cognitive decline in older adults. DOI: 10.1016/j.tjpad.2026.100569. PMCID: PMC13099475. PMID: 42000571. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13099475/
• Adesola Adeniyi Abraham (2026). Validation of the Mizan Meta-Memory and Meta-Concentration Scale for Students (MMSS) among Nigerian health care students. DOI: 10.1186/s40359-026-04647-7. PMCID: PMC13248281. PMID: 42035210. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13248281/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.